Capivasertib for B-Cell Non-Hodgkin Lymphoma

"From what is listed on clinicaltrials.gov, this trial is still looking for participants and is thus actively recruiting patients. The listing was created on 11/3/2021 and last updated on 11/2/2022."

"Capivasertib has been under research for just over a decade now. AstraZeneca first sponsored a trial in 2010, which resulted in Phase 1 approval after studying 285 patients. 23 different studies are ongoing as of now, conducted across 959 cities and 44 countries worldwide."

"Yes, that is accurate. According to the information on clinicaltrials.gov, this particular trial was originally posted on 11/3/2021 and is currently looking for 272 patients from 6 different sites."

"Lymphoma patients that meet the age range of 18 to 130 and have diffuse lymphoma are encouraged to apply for this study. There is a goal of recruiting 272 total participants."

"Capivasertib's safety is only supported by phase 2 data, meaning that there is not yet any clinical evidence indicating that the drug is effective. However, it did receive a score of 2 because there are no major safety concerns at this time."

"Currently, there are six sites administering this trial with more locations in Victoria, Duarte and Los Angeles. To limit participant's travel burden, it is best to select a location closest to you."

"This particular clinical study is open to patients aged 18-130. In contrast, there are 320 trials for minors and 1666 studies available for elderly patients."

"As of now, 23 different clinical trials are underway to research Capivasertib. 4 of these trials have progressed to Phase 3. The majority of the tests for Capivasertib are being conducted in Montpellier, Ontario; however, 4213 unique locations around the world are running studies concerning Capivasertib."